Kenneth C. Carter, Ph.D.

Executive Chairman

Dr. Ken Carter, Executive Chairman, has led several biotechnology companies including NexImmune, Inc., an immuno-oncology company which he helped spin out from John Hopkins University and served as CEO from inception in 2011 until 2017. He also co-founded and is currently Chairman of the Board of Noble Life Sciences, Inc, a pre-clinical contract research organization that enables translational science and product development for biotechnology and pharmaceutical companies. Earlier, Dr. Carter was co-founder and CEO of Avalon Pharmaceuticals from inception in 1999 until the Company’s merger with Clinical Data in 2009 and led Avalon’s initial public offering on the NASDAQ stock exchange in 2004. Under Dr. Carter’s leadership, Avalon developed a pipeline of cancer drug candidates based on a novel high-throughput genomic screening technology and successfully secured R&D; partnerships with Merck, Novartis, Sanofi-Aventis and MedImmune. Dr. Carter has served on numerous corporate and advisory boards including the National BIO Industry Organization, Antidote Therapeutics, Inc., Iterion Pharmaceuticals and the Maryland BioHealth Initiative (BHI). He is also an adjunct faculty member at John Hopkins University.

Cristina Csimma, Pharm.D, MHP


Dr. Cristina Csimma is a seasoned biotechnology executive that has served in senior leadership roles and as a board member for several companies. Currently she also serves as Executive Chair of the Board of Directors of Rheostat Therapeutics (neurodegenerative diseases), on the Board of Directors of Idera Pharmaceuticals (NASDAQ: IDRA), a clinical stage biopharmaceutical company and T1D Exchange, a nonprofit research organization for type 1 diabetes. She also serves on various advisory boards, including: the Muscular Dystrophy Association Venture Philanthropy Scientific Advisory Committee; the Executive Oversight Board to the National Institutes of Health (NIH) NeuroNext Network; the Harvard and Brigham and Women’s Hospital MRCT Center External Advisory Board, and the TREAT-NMD Advisory Committee for Therapeutics (TACT) She was previously the Executive Chair of the Board of Directors of Exonics Therapeutics (acquired by Vertex), a Director of Juniper Pharmaceuticals (acquired by Catalent), Vtesse (acquired Sucampo Pharmaceuticals) and Cydan, where she was also President and founding CEO. Dr. Csimma also served as a Principal at Clarus Ventures LLC and held roles in Clinical Development and Translational Research at Wyeth (now Pfizer), Genetics Institute and Dana Farber Cancer Institute.

Mary Ann Gray, Ph.D.


Dr. Mary Ann Gray has a combination of scientific and financial expertise that provides unique insights for board leadership. She has served on several public-company boards over the last 15 years including: TetraLogic, a publicly-held clinical-stage biopharmaceutical company focused on oncology and infectious diseases, Dyax Corp., a rare disease company acquired by Shire; ACADIA Pharmaceuticals, focused on commercialization of CNS therapies; and Juniper Pharmaceuticals, a supplier of high-end fee-for-service pharmaceutical development and clinical trials, acquired by Catalent. She also currently sits on the board of Sarepta, a precision medicine company with assets in rare neuromuscular diseases, including gene therapy for DMD. Dr. Gray has a distinguished scientific background, completing pharmacology research in tumor biology, including the impact of therapeutics on cardiac membranes. Early in her career Dr. Gray was as a scientist focused on new drug development, she subsequently worked in equities research before becoming a senior analyst and portfolio manager.

David Mazzo, Ph.D.


Dr. Mazzo brings over 35 years of experience in the pharmaceutical industry. He currently serves as President and Chief Executive Officer of Caladrius Biosciences, a clinical-stage biopharmaceutical company committed to the development of innovative products with a focus on select cardiovascular and autoimmune diseases. Dr. Mazzo has also served as: Chief Executive Officer and as a member of the board of directors of Regado Biosciences, Inc., a NASDAQ-listed biopharmaceutical company; President, Chief Executive Officer and a director of Æterna Zentaris, Inc. (NASDAQ: AEZS) and President, Chief Executive Officer and a member of the board of managers of Chugai Pharma USA, LLC, a biopharmaceutical company which was the U.S. subsidiary of Chugai Pharmaceutical Co., Ltd. of Japan. In addition, Dr. Mazzo has also held senior management and executive positions in a number of public and private pharmaceutical and biotech companies.

Scott Ogilvie


Mr. Scott V. Ogilvie has served as a director on Seneca Bio’s board since February 2008. Mr. Ogilvie is currently the President of AFIN International, Inc., an international private equity and strategic advisory firm, which he founded in 2006. Prior to December 31, 2009, he was CEO of Gulf Enterprises International, Ltd, an investment and strategic advisory company with primary activities in the Middle East and North Africa. He held this position since August 2006. Mr. Ogilvie previously served as Chief Operating Officer of CIC Group, Inc., an investment manager, a position he held from 2001 to 2007. He began his career as a corporate and securities lawyer with Hill, Farrer & Burrill, and has extensive public and private corporate management and board experience in finance, real estate, and life science and technology companies. During the past five years, Mr. Ogilvie has served on the board of directors of Innovative Card Technologies, Inc. (OTCBB:INVC), Preferred Voice, Inc., (OTCBB:PRFV), GenSpera, Inc. (OTCQB: GNSZ) and Research Solutions, Inc. (OTCQB:RSSS). His expertise is in both public and private organizations regarding corporate finance, securities and compliance and international business development.

Sandford Smith


Mr. Sandford D. Smith has served on Seneca Bio’s board of directors since March 2014. Since December 2011, Mr. Smith has served as Founder and Chairman of Global Biolink Partners. From 1996 until 2011, Mr. Smith served in various senior and executive management positions at Genzyme Corporation (Formerly NASDAQ:GENZ), including Executive Vice President and President, International Group with responsibility for the commercial activities for Genzyme’s products outside of the U.S. Prior to joining Genzyme, Mr. Smith served from 1986 to 1996 as President and Chief Executive Officer and a Director of Repligen Corporation, a formerly publicly traded biotechnology company. Mr. Smith previously held a number of positions with Bristol-Myers Squibb Company (NYSE: BMY) from 1977 to 1986, including Vice President of Business Development and Strategic Planning for the Pharmaceutical Group. Mr. Smith currently serves as a director of Cytokynetics, Inc. (NASDAQ: CYTK) and Apricus Biosciences, Inc. (NASDAQ: APRI). Mr. Smith serves as a member of the President’s Advisory Board of Brigham and Women’s Hospital in Boston, member of the Advisory Board of Tullis Health Investors in Greenwich, Connecticut and an advisor to BioNEST Partners in New York and Paris. Mr. Smith also is the founder of Smith Scholars, a medical residency program for physicians from resource-poor nations. Mr. Smith has a history of marketing and developing of therapies targeted at rare disease or those with orphan designations as well as his general experience in the biotech industry.

Binxian Wei


Mr. Binxian (Phil) Wei has served on our board of directors since February 2019. He has been the V.P. of Darsheng Trade & Tech. Development Co, Ltd. (a subsidiary to Tianjin Tiayo Pharmaceutical Co., Ltd.) since 2015. He is responsible for API and finished dosage marketing for Chinese pharmaceutical companies. From 2008 through 2010, he worked as a business development manager for Sakai Trading.  He holds a Master’s degree in Mathematical & Computer Sciences from Colorado School of Mines, a Master’s Degree and Bachelor’s Degree in Chemical Engineering from Tianjin University in China.